The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Allogene Therapeutics, Inc. | Common Stock | 019770106 | 4,189,720 | 1,798,163 | SH | SOLE | 1,798,163 | 0 | 0 | |||
Centessa Pharmaceuticals plc | Ordinary Shares | 152309100 | 35,504,317 | 3,931,818 | SH | SOLE | 3,931,818 | 0 | 0 | |||
Dyne Therapeutics, Inc. | Common Stock | 26818M108 | 14,380,640 | 407,499 | SH | SOLE | 407,499 | 0 | 0 | |||
Kronos Bio, Inc. | Common Stock | 50107A104 | 3,428,989 | 2,765,314 | SH | SOLE | 2,765,314 | 0 | 0 | |||
Kyverna Therapeutics, Inc. | Common Stock | 501976104 | 33,929,430 | 4,523,924 | SH | SOLE | 4,523,924 | 0 | 0 |